Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT ID: NCT06324357
Last Updated: 2025-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
768 participants
INTERVENTIONAL
2024-06-03
2029-01-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study, participants receive treatment in cycles. Study participants are treated with zongertinib alone or in combination with other treatments. This study has 2 parts. In Part 1, participants in different groups receive increasing doses of zongertinib. In Part 2, participants are put into different groups by chance. Each group receives a different dose of zongertinib. Every participant has an equal chance of being in each group.
During the study, the participants visit the study site regularly. In this study, researchers want to find the highest dose of zongertinib that participants can tolerate when taken together with other treatments. To find this out, researchers look at certain severe health problems that a number of participants have. The doctors regularly check the size of the tumour with imaging methods (CT/MRI) during the study. The doctors also regularly check participants' health and take note of any unwanted effects.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase Ib - Cohort A: zongertinib + Trastuzumab emtansine
Dose escalation (Phase Ib)
Zongertinib
Zongertinib
Trastuzumab emtansine
Trastuzumab emtansine
Phase Ib - Cohort B: zongertinib + Trastuzumab deruxtecan
Dose escalation (Phase Ib)
Zongertinib
Zongertinib
Trastuzumab deruxtecan
Trastuzumab deruxtecan
Phase Ib - Cohort C: zongertinib + Trastuzumab deruxtecan
Dose escalation (Phase Ib)
Zongertinib
Zongertinib
Trastuzumab deruxtecan
Trastuzumab deruxtecan
Phase II - Cohort D: zongertinib + Trastuzumab emtansine
Dose optimization (Phase II).
Zongertinib
Zongertinib
Trastuzumab emtansine
Trastuzumab emtansine
Phase II - Cohort E: zongertinib + Trastuzumab deruxtecan
Dose optimization (Phase II).
Zongertinib
Zongertinib
Trastuzumab deruxtecan
Trastuzumab deruxtecan
Phase II - Cohort F: zongertinib + Trastuzumab deruxtecan
Dose optimization (Phase II).
Zongertinib
Zongertinib
Trastuzumab deruxtecan
Trastuzumab deruxtecan
Phase Ib - Cohort G: zongertinib + trastuzumab + capecitabine
Dose escalation (Phase Ib)
Zongertinib
Zongertinib
Trastuzumab
Herceptin®
Capecitabine
Xeloda®
Phase Ib - Cohort K: zongertinib + trastuzumab
Dose escalation (Phase Ib)
Zongertinib
Zongertinib
Trastuzumab
Herceptin®
Phase II - Cohort H: zongertinib + trastuzumab + capecitabine
Dose optimization (Phase II).
Zongertinib
Zongertinib
Trastuzumab
Herceptin®
Capecitabine
Xeloda®
Phase II - Cohort I: zongertinib
Dose optimization (Phase II).
Zongertinib
Zongertinib
Phase II - Cohort J: zongertinib + trastuzumab
Dose optimization (Phase II).
Zongertinib
Zongertinib
Trastuzumab
Herceptin®
Phase II - Cohort I-ext: zongertinib
Extension Phase II
Zongertinib
Zongertinib
Phase II - Cohort J-ext: zongertinib + trastuzumab
Extension Phase II
Zongertinib
Zongertinib
Trastuzumab
Herceptin®
Phase Ib - Cohort M: zongertinib + mFOLFOX6
Dose escalation (Phase Ib)
Zongertinib
Zongertinib
mFOLFOX6
mFOLFOX6
Phase Ib - Cohort N: zongertinib + trastuzumab + mFOLFOX6
Dose escalation (Phase Ib)
Zongertinib
Zongertinib
Trastuzumab
Herceptin®
mFOLFOX6
mFOLFOX6
Phase Ib - Cohort O: zongertinib + zanidatamab
Dose escalation (Phase Ib) - is not conducted in China or South Korea
Zongertinib
Zongertinib
zanidatamab
zanidatamab
Phase II - Cohort L: zongertinib + trastuzumab
Dose justification (Phase II)
Zongertinib
Zongertinib
Trastuzumab
Herceptin®
Phase II - Cohort L-ext: zongertinib + trastuzumab
Extension Phase II
Zongertinib
Zongertinib
Trastuzumab
Herceptin®
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zongertinib
Zongertinib
Trastuzumab deruxtecan
Trastuzumab deruxtecan
Trastuzumab emtansine
Trastuzumab emtansine
Trastuzumab
Herceptin®
Capecitabine
Xeloda®
mFOLFOX6
mFOLFOX6
zanidatamab
zanidatamab
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cohorts A to K and Cohort O: Documented Human epidermal growth factor receptor 2 overexpressing and/or amplified (HER2+), metastatic breast cancer (mBC) or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma (mGEAC).
* Cohorts L (L-ext), M, and N (metastatic colorectal cancer (mCRC)): Documented Human epidermal growth factor receptor 2 (HER2) overexpression/amplification according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) gastric cancer guidelines and according to the result of local testing.
* For dose optimization and justification (Phase II): Patient must provide tumor tissue from locations not radiated prior to biopsy, if possible, collected through archival tissue
* History of prior treatment lines in palliative setting:
* For cohorts A, B, C, D, E, F, G, H, I, I-ext, J, J-ext, K and O documented investigator assessed progression after HER2-directed treatment for unresectable locally advanced or metastatic disease (For Cohorts D, H, I (I-ext), J (J-ext) - patients must have been pretreated with trastuzumab deruxtecan (T-DXd) and have progressed or have been intolerant to previous T-DXd).
* For cohorts L, L-ext, M and N documented progression or recurrence of disease during or following their latest line of therapy. Patients must have had at least one prior line of therapy for locally advanced unresectable disease or metastatic disease (adjuvant and neoadjuvant therapy excluded) and documented disease progression or recurrence of disease during or following their latest line of therapy. In the opinion of the Investigator, patients must be unlikely to tolerate or derive clinically meaningful benefit from further standard of care therapy known to prolong survival.
* Presence of at least one measurable lesion according to RECIST 1.1
* Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
Exclusion Criteria
* Any small molecule HER2 inhibitor in the palliative setting in Cohorts D, E, F, H, L, L-ext, M, and N. In Cohort D allowed in up to 15 patients in each dose level (DL).
* T-DXd in Cohorts E and F. In Cohort E allowed in up to 15 patients in each DL.
* trastuzumab emtansine (T-DM1) in the palliative setting in Cohort D and H. In Cohort H allowed in up to 15 patients in each DL.
* Capecitabine in Cohort D and H. In Cohort D allowed in up to 15 patients in each DL
* Presence of uncontrolled and/or symptomatic brain metastases, or leptomeningeal disease
* Mean resting corrected QT interval (QT interval corrected for heart rate by Fridericia´s formula (QTcF)) \>470 msec.
* Any factors that increase the risk of QT interval corrected for heart rate (QTc) prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, personal or family history of long QT syndrome or unexplained sudden death under 40 years-of-age.
* Ejection fraction \<50% or the lower limit of normal of the institutional standard within 28 days prior to randomization
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic-Arizona
Phoenix, Arizona, United States
The Oncology Institute of Hope and Innovation
Cerritos, California, United States
Ellison Medical Institute
Los Angeles, California, United States
Valkyrie Clinical Trials
Los Angeles, California, United States
University of California Los Angeles
Los Angeles, California, United States
University of California Irvine
Orange, California, United States
Sharp Memorial Hospital
San Diego, California, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Mayo Clinic - Florida
Jacksonville, Florida, United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Community Health Network
Indianapolis, Indiana, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Mayo Clinic, Rochester
Rochester, Minnesota, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
Avera Cancer Institute
Sioux Falls, South Dakota, United States
Baptist Cancer Center - Memphis
Memphis, Tennessee, United States
SCRI Oncology Partners
Nashville, Tennessee, United States
Tennessee Oncology, Pllc
Nashville, Tennessee, United States
The Methodist Hospital Research Institute
Houston, Texas, United States
Inova Schar Cancer Institute
Fairfax, Virginia, United States
Virginia Cancer Specialists, PC
Fairfax, Virginia, United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Cliniques Universitaires Saint-Luc
Brussels, , Belgium
Edegem - UNIV UZ Antwerpen
Edegem, , Belgium
UZ Leuven
Leuven, , Belgium
Hôpital Vivalia De Libramont
Libramont-Chevigny, , Belgium
Centre Hospitalier Universitaire de Liège
Liège, , Belgium
CHU UCL Namur
Namur, , Belgium
Jilin Province Cancer Hospital
Changchun, , China
The First Hospital of Jilin University
Changchun, , China
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
Hangzhou, , China
Harbin Medical University Cancer Hospital
Harbin, , China
Jiangsu Province Hospital
Nanjing, , China
Fudan University Shanghai Cancer Center
Shanghai, , China
Tianjin Cancer Hospital
Tianjin, , China
Henan Cancer Hospital
Zhengzhou, , China
INS Bergonie
Bordeaux, , France
CTR François Baclesse
Caen, , France
CTR Georges-François Leclerc
Dijon, , France
CTR Leon Berard
Lyon, , France
INS Paoli-Calmettes
Marseille, , France
HOP Tenon
Paris, , France
CTR Eugène Marquis
Rennes, , France
Institut de Cancérologie de l'Ouest
Saint-Herblain, , France
Institut de Cancérologie de Strasbourg
Strasbourg, , France
INS Claudius Regaud IUCT-Oncopole
Toulouse, , France
INS Gustave Roussy
Villejuif, , France
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, , Germany
Universitätsklinikum Erlangen
Erlangen, , Germany
Evang. Kliniken Essen-Mitte gGmbh
Essen, , Germany
Asklepios Kliniken GmbH & Co. KGaA
Hamburg, , Germany
Universitätsklinikum Mannheim GmbH
Mannheim, , Germany
Universitätsklinikum Ulm
Ulm, , Germany
Istituto Di Candiolo
Candiolo (TO), , Italy
Az.Osp. Universitaria "Ospedali Riuniti"
Foggia, , Italy
Istituto Scientifico Romagnolo
Meldola (FC), , Italy
Ospedale San Raffaele S.r.l.
Milan, , Italy
Istituto Europeo di Oncologia
Milan, , Italy
Humanitas Istituto Clinico Catanese S.p.A.
Misterbianco (CT), , Italy
Istituto Nazionale IRCCS Tumori Fondazione Pascale
Napoli, , Italy
Istituto Clinico Humanitas
Rozzano, , Italy
Aichi Cancer Center Hospital
Aichi, Nagoya, , Japan
Tokai University Hospital
Isehara, , Japan
Hakuaikai Sagara Hospital
Kagoshima, , Japan
Kanagawa Cancer Center
Kanagawa, Yokohama, , Japan
National Cancer Center Hospital East
Kashiwa-shi, , Japan
Kyoto University Hospital
Kyoto, Kyoto, , Japan
Osaka International Cancer Institute
Osaka, , Japan
Japanese Foundation for Cancer Research
Tokyo, Koto-ku, , Japan
CHA Bundang Medical Center
Seongnam-si, , South Korea
Seoul National University Bundang Hospital
Seongnam-si, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Korea University Anam Hospital
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
The Catholic University of Korea, Seoul St.Mary's Hospital
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Hospital Teresa Herrera
A Coruña, , Spain
Hospital del Mar
Barcelona, , Spain
Hospital Universitari Vall D Hebron
Barcelona, , Spain
Hospital Clínic de Barcelona
Barcelona, , Spain
Hospital Duran i Reynals
L'Hospitalet de Llobregat, , Spain
Hospital General Universitario Gregorio Marañón
Madrid, , Spain
Clínica Universidad de Navarra - Madrid
Madrid, , Spain
Fundación Jiménez Díaz
Madrid, , Spain
Hospital Clínico San Carlos
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Universitario La Paz
Madrid, , Spain
CIO Clara Campal
Madrid, , Spain
Hospital Universitario Virgen De La Macarena
Seville, , Spain
Instituto Valenciano de Oncología
Valencia, , Spain
Velindre Cancer Centre
Cardiff, , United Kingdom
St James's University Hospital
Leeds, , United Kingdom
St Bartholomew's Hospital
London, , United Kingdom
University College Hospital
London, , United Kingdom
Royal Free Hospital
London, , United Kingdom
The Christie
Manchester, , United Kingdom
Nottingham University Hospitals NHS Trust
Nottingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
Boehringer Ingelheim
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Hurvitz S, Simonelli M, Yarza R, Berz D, Kitano S, Del Conte G, Acosta Eyzaguirre D, Doger de Speville Uribe BG, Maier D, Erzen D, Aykut Yazgili S, Curigliano G, Deng T, Yan M, Zhang Q, Wang X, Nakayama I, Shitara K. Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers. Future Oncol. 2025 Nov;21(26):3385-3393. doi: 10.1080/14796694.2025.2569553. Epub 2025 Oct 17.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1479-0012
Identifier Type: -
Identifier Source: org_study_id